Advertisement

Topics

FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia

07:00 EDT 6 Jun 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
— First and Only Long-Acting Atypical Antipsychotic With Two-Month Dosing Option — — Approval Expands ARISTADA’s Product Offerings to Include Once-Monthly, Once-Every-Six-Weeks and Once-Every-Two-Months Dosing ...

Other Sources for this Article

Alkermes
For Investors:
Eva Stroynowski, +1 781-609-6823
or
Sandy Coombs, +1 781-609-6377
or
For Media:
Lindsey Smith, +1 781-609-6231

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia"

Quick Search
Advertisement
 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...